WO2008152508A3 - Cytokine conjugate - Google Patents

Cytokine conjugate Download PDF

Info

Publication number
WO2008152508A3
WO2008152508A3 PCT/IB2008/002021 IB2008002021W WO2008152508A3 WO 2008152508 A3 WO2008152508 A3 WO 2008152508A3 IB 2008002021 W IB2008002021 W IB 2008002021W WO 2008152508 A3 WO2008152508 A3 WO 2008152508A3
Authority
WO
WIPO (PCT)
Prior art keywords
subunit
peptide
cytokine conjugate
dgr
ngr
Prior art date
Application number
PCT/IB2008/002021
Other languages
French (fr)
Other versions
WO2008152508A2 (en
Inventor
Catia Traversari
Barbara Valentinis
Sylvia Tanzarella
Angelo Corti
Salvatore Toma
Original Assignee
Molmed Spa
Martucci, Anna Maria
Toma, Caterina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molmed Spa, Martucci, Anna Maria, Toma, Caterina filed Critical Molmed Spa
Publication of WO2008152508A2 publication Critical patent/WO2008152508A2/en
Publication of WO2008152508A3 publication Critical patent/WO2008152508A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An IL12 heterodimer comprising a p35 subunit and a p40 subunit wherein the p40 subunit is conjugated to a first peptide containing the NGR, DGR or isoDGR motif and the p35 subunit is optionally conjugated to a second peptide containing the NGR, DGR or isoDGR motif and wherein the sequence of the first peptide and the sequence of the second peptide may be the same or different.
PCT/IB2008/002021 2007-05-08 2008-05-07 Cytokine conjugate WO2008152508A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92430707P 2007-05-08 2007-05-08
GB0708864.4 2007-05-08
US60/924,307 2007-05-08
GBGB0708864.4A GB0708864D0 (en) 2007-05-08 2007-05-08 Cytokine Conjugate

Publications (2)

Publication Number Publication Date
WO2008152508A2 WO2008152508A2 (en) 2008-12-18
WO2008152508A3 true WO2008152508A3 (en) 2009-11-05

Family

ID=38198912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002021 WO2008152508A2 (en) 2007-05-08 2008-05-07 Cytokine conjugate

Country Status (2)

Country Link
GB (1) GB0708864D0 (en)
WO (1) WO2008152508A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346362B (en) 2009-11-10 2017-03-15 Allegro Pharmaceuticals Inc * Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites.
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
US9657077B2 (en) * 2011-02-11 2017-05-23 Board Of Supervisors Of Louisiana State Carcinoma homing peptide (CHP), its analogs, and methods of using
SG11201604781RA (en) * 2013-12-18 2016-07-28 Intrexon Corp Single chain il-12 nucleic acids, polypeptids, and uses thereof
EP3642219A4 (en) * 2017-06-19 2021-06-09 Allegro Pharmaceuticals, LLC Peptide compositions and related methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093478A1 (en) * 2002-04-30 2003-11-13 Molmed Spa Immunoconjugates for the treatment of tumours
WO2003092737A1 (en) * 2002-04-30 2003-11-13 Molmed Spa Fusions of cytokines and tumor targeting proteins
WO2006067633A2 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product
WO2008064910A2 (en) * 2006-11-30 2008-06-05 Università Degli Studi Di Torino Metastasis-specific peptides and their diagnostic and therapeutic applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093478A1 (en) * 2002-04-30 2003-11-13 Molmed Spa Immunoconjugates for the treatment of tumours
WO2003092737A1 (en) * 2002-04-30 2003-11-13 Molmed Spa Fusions of cytokines and tumor targeting proteins
WO2006067633A2 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product
WO2008064910A2 (en) * 2006-11-30 2008-06-05 Università Degli Studi Di Torino Metastasis-specific peptides and their diagnostic and therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DICKERSON E. B. AT AL.: "enhancement of the Antiangiogenic Activity of Interleukin-12 by Peptide targeted Delivery of the Cytokine to alphav beta3 Integrin", MOL CANCER RES, vol. 2, no. 12, 2004, pages 663 - 673, XP007909776 *
DWYER D. S.: "Molecular model of interleukin 12 that highlights amino acid sequence homologies with adhesion domains and gastrointestinal peptides", JOURNAL OF MOLECULAR GRAPHICS, vol. 14, 1996, pages 148 - 157, XP007909775 *

Also Published As

Publication number Publication date
GB0708864D0 (en) 2007-06-13
WO2008152508A2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
ECSP088501A (en) CRYSTALLINE SHAPE OF 1´- (1-METHYTILE) -4´ - [(2-FLUORO-4-METOXIFENIL) METHYL] -5´-METHYL-1H-PIRAZOL-3´-O-ß-D-GLUCOPIRANOSIDE, A METHOD FOR YOUR PREPARATION AND THE USE OF THE SAME TO PREPARE MEDICATIONS
WO2005074546A3 (en) Modified human growth hormone polypeptides and their uses
MX2010005889A (en) Novel thiophene derivatives.
EA200701053A1 (en) PRODUCT CONVENTIONS
NZ577392A (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
MY154909A (en) Novel thiophene derivatives
EP2450041A3 (en) Improved testosterone gel and method of use
ME01192B (en) N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use
EP1637167A3 (en) New injectable formulations containing progesterone
WO2008152508A3 (en) Cytokine conjugate
WO2008057780A3 (en) Transdermal delivery of ketoprofen polar derivatives
ITTO20040390A1 (en) COMPOSITION, IN PARTICULAR FOR PHARMACEUTICAL USE, WITH ANTIOXIDANT, ANTI-INFLAMMATORY AND IMMUNOSTIMULATING ACTION.
CA115208S (en) Dispenser
WO2006087354A3 (en) Insulinotropic agents conjugated with structurally well defined branched polymers
WO2006066950A3 (en) Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents
WO2009023662A3 (en) Water-resistant, rub-resistant, sprayable, homogeneous sunscreen composition
WO2007144521A3 (en) Cosmetic composition for topical use comprising wasabi
WO2006029398A3 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
EP1717246B8 (en) Tnf antagonists and tnf inhibitors comprising the same as the active ingredient
PA8644701A1 (en) DERIVATIVES OF ALQUILIDEN-TETRAHIDRONAFTALENO, PROCEDURE FOR ITS PREPARATION AND ITS USE AS ANTI-INFLAMMATORIES
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
GT200500268A (en) INHIBITORS OF THE SOLUBLE CYCLING ADENYLATE
AU2003220523A1 (en) Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
WO2006069182A3 (en) THIENOISOQUINOLINE-PHENYLSULFONAMIDES AND THEIR USE AS ER-NFkB INHIBITORS
CA98132S (en) Tabletop folder/inserter

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08806876

Country of ref document: EP

Kind code of ref document: A2